.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Federal Trade Commission
Harvard Business School
Cipla
Deloitte
Chinese Patent Office
Moodys
Boehringer Ingelheim
UBS
Chubb

Generated: July 26, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 6,871,646 protect, and when does it expire?


Patent ► Subscribe protects PROAIR RESPICLICK, ARMONAIR RESPICLICK, and AIRDUO RESPICLICK, and is included in three NDAs.

This patent has eighty-three patent family members in eighteen countries.

Summary for Patent: ► Subscribe

Title: De-agglomerator for breath-actuated dry powder inhaler
Abstract:A de-agglomerator is provided for use with a breath-actuated dry powder inhaler for breaking up aggregates and micronizing particles of dry powder prior to inhalation of the powder by a patient using the inhaler. The de-agglomerator includes an inner wall defining a swirl chamber extending along an axis from a first end to a second end, a dry powder supply port, an inlet port, and an outlet port. The supply port is in the first end of the swirl chamber for providing fluid communication between a dry powder delivery passageway of an inhaler and the first end of the swirl chamber. The inlet port is in the inner wall of the swirl chamber adjacent to the first end of the swirl chamber and provides fluid communication between a region exterior to the de-agglomerator and the swirl chamber. The outlet port provides fluid communication between the second end of the swirl chamber and a region exterior to the de-agglomerator, whereby a breath induced low pressure at the outlet port causes air flows into the swirl chamber through the dry powder supply port and the inlet port. The air flows collide with each other and with the wall of the swirl chamber prior to exiting through the outlet port, such that any powder entrained in the air flows is broken down and micronized. The de-agglomerator further includes vanes at the first end of the swirl chamber for creating additional collisions and impacts of entrained powder.
Inventor(s): Keane; Laurence (Aldwick, GB), O'Leary; David (Essex, GB)
Assignee: Norton Healthcare Ltd. (London, GB)
Application Number:10/837,004
Patent Claim Types:
see list of patent claims
Use; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Teva Branded Pharm
PROAIR RESPICLICK
albuterol sulfate
POWDER, METERED;INHALATION205636-001Mar 31, 2015RXYesYes► Subscribe► SubscribeY
Teva Pharm
ARMONAIR RESPICLICK
fluticasone propionate
POWDER;INHALATION208798-001Jan 27, 2017RXYesNo► Subscribe► SubscribeY
Teva Pharm
ARMONAIR RESPICLICK
fluticasone propionate
POWDER;INHALATION208798-002Jan 27, 2017RXYesNo► Subscribe► SubscribeY
Teva Pharm
ARMONAIR RESPICLICK
fluticasone propionate
POWDER;INHALATION208798-003Jan 27, 2017RXYesYes► Subscribe► SubscribeY
Teva Pharm
AIRDUO RESPICLICK
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION208799-001Jan 27, 2017RXYesNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,006,690Reservoir pressure system for medicament inhaler► Subscribe
6,655,381 Pre-metered dose magazine for breath-actuated dry powder inhaler► Subscribe
6,718,972 Dose metering system for medicament inhaler► Subscribe
7,540,282Reservoir pressure system for medicament inhaler► Subscribe
6,748,947 De-agglomerator for breath-actuated dry powder inhaler► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI224515► Subscribe
TaiwanI224514► Subscribe
TaiwanI224513► Subscribe
TaiwanI224512► Subscribe
TaiwanI224511► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
QuintilesIMS
US Army
Teva
Harvard Business School
Colorcon
Julphar
Deloitte
UBS
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot